46-60 of 88
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
Daniel Gaudet, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
MinuteCE®Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
APOC3 Inhibition: A Novel Approach to Lowering TGs
MinuteCE®APOC3 Inhibition: A Novel Approach to Lowering TGs
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
- advertisement
Latest Clinical Trial Outcomes and Breakthroughs for FCS
MinuteCE®Latest Clinical Trial Outcomes and Breakthroughs for FCS
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
SHTG: Decoding the Latest Clinical Trial Outcomes
MinuteCE®SHTG: Decoding the Latest Clinical Trial Outcomes
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Remnant Cholesterol: The Missing Link in ASCVD risk
MinuteCE®Remnant Cholesterol: The Missing Link in ASCVD risk
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
MinuteCE®Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
The Road Ahead: What's on the Horizon for FCS and SHTG Management
MinuteCE®The Road Ahead: What's on the Horizon for FCS and SHTG Management
Pam R. Taub, MD, FACC, FASPC
Prof. Kausik Ray
- advertisement
Harry Yoon, MD
Jaffer Ajani, MD
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Harry Yoon, MD
